<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211507</url>
  </required_header>
  <id_info>
    <org_study_id>16SM3627</org_study_id>
    <nct_id>NCT03211507</nct_id>
  </id_info>
  <brief_title>Idiopathic Pulmonary Fibrosis Job Exposures Study</brief_title>
  <acronym>IPFJES</acronym>
  <official_title>Idiopathic Pulmonary Fibrosis Job Exposures Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College Healthcare NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart of England NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papworth Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of South Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Bristol NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Somerset NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Infirmary of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Morriston Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aberdeen Royal Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worcestershire Acute Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Portsmouth Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norfolk and Norwich University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glasgow Royal Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case-control study to investigate whether job exposures are an under-recognized cause of
      idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous
      jobs and a blood test to investigate genetic susceptibility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is a scarring lung disease. It damages the air sacs that
      allow oxygen to be transferred into the blood and transported to vital organs. These changes
      make people with IPF cough and feel short of breath. It not known what causes the damage.
      People who get IPF are usually older than 40Í¾ it's a very serious illness that cannot be
      cured and gets worse over time. Statistics show that IPF is becoming more common in the UK
      but it's not known why. It can be difficult for doctors to tell if someone has IPF or another
      disease called asbestosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">October 5, 2019</completion_date>
  <primary_completion_date type="Actual">October 5, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association between asbestos exposure and IPF</measure>
    <time_frame>2 years</time_frame>
    <description>estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-response relationship between asbestos exposure and IPF</measure>
    <time_frame>2 years</time_frame>
    <description>estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio.</measure>
    <time_frame>2 years</time_frame>
    <description>MUC5B rs35705950 and asbestos exposure odds ratio.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">960</enrollment>
  <condition>IPF</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computer-assisted telephone interview</intervention_name>
    <description>Occupational history</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic analysis</intervention_name>
    <description>To include analysis of known susceptibility markers</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital based
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For cases

        Inclusion Criteria:

          -  New diagnosis of IPF between February 2017 and October 2019

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Ever worked outside of the UK

        For controls

        Inclusion Criteria:

          -  New outpatient department attendee between February 2017 and October 2019

        Exclusion Criteria:

          -  Unable to give informed consent

          -  Ever worked outside of the UK (does not include work outside the UK by members of the
             armed forces or merchant navy)

          -  Diagnosis of IPF
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl Reynolds</last_name>
    <role>Study Director</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://github.com/drcjar/ipfjes/blob/master/README.md</url>
    <description>Full study documentation</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Idiopathic Pulmonary Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

